ReviewHuman vaccines & immunotherapeutics2025
Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.
Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Determinants of severity in immune checkpoint inhibitor-related pneumonitis: clinical, radiologic, and laboratory insights from real-life clinical data.BMC cancer · 2026Article
- Sintilimab-Induced Sequential Multi-System Severe Immune-Related Adverse Events in an Elderly Patient with Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review.OncoTargets and therapy · 2026Article
- Bronchoalveolar lavage fluid in immune checkpoint inhibitor-related pneumonitis: from pathophysiological window to a precision diagnostic tool.Frontiers in immunology · 2026Review
- Identification of Prognostic Clinical Features in Grade 4 Immune-Related Adverse Events: A Triangulation Study.ImmunoTargets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of immune checkpoint inhibitors (ICIs) - including ipilimumab, nivolumab, and atezolizumab has demonstrated remarkable clinical efficacy in cancer therapy. However, due to the activation of the immune system, ICIs can also precipitate immune-related adverse events (irAEs) across multiple organ systems. Among these toxicities, checkpoint inhibitor-related pneumonitis (CIP) is uncommon but carries substantial mortality and poses notable diagnostic and therapeutic challenges. In this review, we summarize the current advances regarding the risk factors and mechanisms of CIP and provide an overview of its incidence and mortality, imaging characteristics, diagnostic approaches, and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.